Mechanistic basis for impaired B cell depletion after anti-CD20 treatment of African American with neuro-inflammatory disorders

Brief description of study

The purpose of this research is to better understand why African Americans with Multiple Sclerosis (MS), Neuromyelitis optica (NMO), or other neuroinflammatory disorders, have fast B-cell repopulation after receiving anti-CD20 therapies such as Rituximab and Ocrelizumab. The researchers plan to collect up to 30.5 mL (2.1 tbsp) of blood sample for each subject at a single time-point during the bi-annual clinic visit that is immediately prior to scheduled aCD20 infusion. For each subject, per our standard of care the researchers plan to collect routine clinical studies as well as the research labs. Blood samples will be analyzed at NYU specialty laboratories according to the appropriate workflow as specified in the Lab Manual.


Clinical Study Identifier: s22-00483


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.